Crinetics Pharmaceuticals, Inc. (CRNX)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $84.95
- As of
Kresmion compiles this page from CRNX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Crinetics Pharmaceuticals, Inc. (CRNX): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-01.
See the full CRNX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for CRNX on one page. Preview it with sample data, then open it live with a free account.
Preview the CRNX dossierActive signals for CRNX
- mediumtrend_spike
Crinetics Pharmaceuticals, Inc. search volume spiked +100 pts, unusual interest
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +91% to CRNX (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +1283% to CRNX (2026Q2)
- highINSTITUTIONAL_EXIT
Point72 Asset Management, L.P. cut 98% of CRNX (2026Q2)
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 7.6%, EPS $-1.14 vs $-1.2332 estimate
FREE, NO ACCOUNT
Every signal on CRNX, as it fires
You are seeing 5 of 8 signals recorded on CRNX since 2026-05-24.
The five above landed across 3 days. The other 3 were recorded on 1 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in CRNX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 22663K107 · 2026Q2 | $5.2M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 22663K107 · 2026Q2 | $3.3M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 22663K107 · 2026Q2 | $1.7M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, CRNX
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
CRNX against its peers
CRNX's operating margin of -6714.8% ranks in the 3rd percentile of 15 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2026-03-31.
| Metric | CRNX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 7.7M USD | 502M USD | 14 | 17 |
| Operating margin | -6714.8% | -31.3% | 3 | 15 |
| Net margin | -6046.2% | -30.1% | 3 | 15 |
| Return on equity | -46.9% | -21.7% | 33 | 19 |
| P / E | n/a | 30.6x | n/a | 5 |
| 1 year | n/a | 65.5% | n/a | 19 |
Peers (23): CYTK, KYMR, PTGX, TGTX, CAI, NUVL, ARWR, KRYS, SYRE, ABVX, APGE, MDGL, IONS, BMRN, IBRX, PCVX, PRAX, ALKS, IOVA, HALO, KOD, BBIO, IMVT. Left out: BCHMY (no annual filing), SBMFF (no annual filing). Fiscal periods ending between 2025-09-30 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (CRNX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow CRNX on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to CRNX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.